DRUG · Unmapped registry intervention
Fimasartan
Find medicine records ·
Find other trials using this name
Clinical trial
Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients
NCT02312375
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Amlodipine
Normalized identity: amlodipineView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedEffects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients
Design: INTERVENTIONAL · Status: COMPLETED · Phase: NA
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Diabetes Mellitusverified · MONDO: diabetes mellitus
Hypertensionunresolved
Interventions
FimasartanDRUG
AmlodipineDRUG · verified · RxNorm: amlodipine
Sponsors & collaborators
Seoul National University Hospitallead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02312375 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.